title: Ongoing trials in Alzheimer's disease.
abstract: Researchers have sought to understand the underlying pathophysiology of Alzheimer's disease (AD) ever since Dr A Alzheimer first described the condition in 1907. Unfortunately however, until recently, they have done so with limited success. This lack of clarity has deterred advancements in therapeutic drug research beyond all but the purely symptomatic treatment relief currently available. However, through spatio-temporal analysis of the two types of cerebral lesions that characterise the disorder (senile plaques and neurofibrillary tangles) and the compilation of genetic data concerning familial AD, there now exists the foundation for a more comprehensive understanding of the disease. Although symptomatic cholinergic strategies have beneficial effects, their benefits are modest and current research has turned to the development of other promising strategies, including oestrogen replacement, anti-inflammatory agents, free radical scavengers, anti-oxidants and monoamine oxidase-B (MAO-B) inhibitors. Many of these strategies may have some merit, however further analysis and structured research are necessary before a definitive decision can be made about their efficacy and possible role in AD therapy. Strategies that are directed at halting the underlying biochemical changes in AD are nearing clinical testing and offer the promise for meaningful therapeutic outcomes.
authors.affiliation: California Clinical Trials, 8500 Wilshire Boulevard, 7th Floor, Beverly Hills, CA 90211, USA. jsramek@cctrials:com
authors.forename: J J
authors.initials: JJ
authors.lastname: Sramek
authors.forename: N R
authors.initials: NR
authors.lastname: Cutler
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000453:epidemiology; D000818:Animals; D000975:Antioxidants / Q000627:therapeutic use*; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D015914:Estrogen Replacement Therapy; D005260:Female; D016166:Free Radical Scavengers / Q000627:therapeutic use*; D006801:Humans; D008996:Monoamine Oxidase Inhibitors / Q000627:therapeutic use*; D012307:Risk Factors
chemical_list: D000975:Antioxidants; D002800:Cholinesterase Inhibitors; D016166:Free Radical Scavengers; D008996:Monoamine Oxidase Inhibitors